Phase 2 trial of deucravacitinib in psoriatic arthritis: Biomarkers associated with disease activity, pharmacodynamics, and clinical responses

FitzGerald, et al. found that Deucravacitinib significantly impacted biomarkers associated with TYK2 signalling pathways of key inflammatory cytokines, including IL-23 and Type I IFN, and those related to collagen matrix turnover.

This Phase 2 study compared deucravacitinib 12mg and 6mg doses to placebo over a 16-week period. Serum biomarkers associated with the IL-23 pathway, Type I IFN pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (PASI75 and ACR20) were measured at Week 16, while hematologic variables were also assessed.